Table 1 Demographic and Disease characteristics in each group
PsA (n = 31) | PsO (n = 35) | Controls (n = 35) | p value* | |
|---|---|---|---|---|
Gender – n(%) | ||||
Female | 16 (51.6) | 18 (51.4) | 21 (60.0) | 0.767 |
Male | 15 (48.4) | 17 (48.6) | 14 (40.0) | |
Age (years) – | ||||
mean ± SD | 53.03 ± 9.64 | 54.46 ± 11.43 | 53.37 ± 10.80 | 0.521 |
Havy manual labor – n(%) | 25 (80.6) | 28 (80.0) | 25 (71.4) | 0.692 |
Comorbidities – n(%) | ||||
HBP | 12 (38.7) | 13 (37.1) | 13 (37.1) | 0.99 |
DM | 7 (22.6) | 8 (22.9) | 3 (8.6) | 0.217 |
Smoking | 5 (16.1) | 5 (14.3) | 3 (8.6) | 0.627 |
PsO Family History– n(%) | 11 (35.5) | 19 (54.3) | 3 (8.6) | < 0.001 |
Mean duration of cutaneous PsO (years) – mean ± SD | 18.81 ± 10.73 | 16.16 ± 10.33 | – | 0.311 |
PASI – m [P25% - P75%] | (n = 13) 1.0 [0.70–4.15] | (n = 24) 3.75 [1.15–5.83] | – | 0.171 |
With clinical nail involvment – n(%) | 15 (48.4) | 19 (54.3) | – | 0.805 |
NAPSI – m [P25% - P75%] | (n = 15) 20 [4–34] | (n = 19) 11 [5–33] | – | 0.891 |
PsO/PsA Current Treatment n(%) | ||||
MTX | 18 (58.1) | 17 (48.6) | – | 0.600 |
Phototherapy | 3 (9.7) | 7 (20.0) | – | 0.410 |
Immunobiological | 10 (32.3) | 4 (11.4) | – | 0.078 |
Corticosteroids | 6 (19.3) | 0 (0.0) | – | 0.003 |
Any systemic treatment | 27 (77.1) | 21 (60.0) | – | 0.029 |